Clinical Trial

A next-gen immunotherapy enters trials, hoping its safer design can unlock the immune system and form a potent combo against advanced solid tumors.

Amid a relentless outbreak, Brazil launches a massive pilot program for the IXCHIQ® vaccine, a critical test for public health and global preparedness.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

Bolstered by a massive capital infusion and strong investor demand, Vaxcyte is set to accelerate its broad-spectrum vaccine pipeline against market leaders.

A new partnership adds dedicated cellular connectivity to a hip-protecting airbag belt, offering seniors and caregivers unparalleled safety and peace of mind.

Praxis and SEQSTER expand their alliance, leveraging a powerful data platform to speed up development of new treatments for epilepsy and other CNS disorders.

MAPS and Columbia University launch a landmark study into MDMA-assisted couples therapy, seeking to turn decades of underground practice into a safe future.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

Ensem Therapeutics expands its global trial for ETX-636, a next-gen cancer drug designed to avoid common toxicities, into China's vast patient market.

Brainomix launches its award-winning stroke AI platform with novel Net Water Uptake tech, promising to improve diagnoses, treatment decisions, and patient outcomes.

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

ALX Oncology data shows CD47 levels predict response to evorpacept, offering new hope for heavily pretreated patients in a crowded therapeutic landscape.

A new dual-action tablet shows major promise for prostate cancer patients with BRCA mutations, poised to change the standard of care in Europe.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

Tonix Pharmaceuticals' newly approved drug, TONMYA, offers a breakthrough for millions, using unique science to combat the chronic pain of fibromyalgia.

A groundbreaking implantable cell therapy shows consistent, positive results for a debilitating complication of Crohn's disease, paving an expedited path to market.

A German biotech's novel oral drug for herpes is moving to Phase 2 trials, offering new hope against a widespread and often resistant virus.

As its promising prostate cancer drug nears Phase 3, Convergent Therapeutics hires a new CPO to build the team for its next critical growth phase.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.